- Home
- PROK vs MDXH Comparison
PROK vs MDXH Comparison
Compare PROK & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- MDXH
- Stock Information
- Founded
- PROK 2015
- MDXH 2003
- Country
- PROK United States
- MDXH Belgium
- Employees
- PROK N/A
- MDXH N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- MDXH
- Sector
- PROK Health Care
- MDXH
- Exchange
- PROK Nasdaq
- MDXH Nasdaq
- Market Cap
- PROK 85.5M
- MDXH 84.6M
- IPO Year
- PROK N/A
- MDXH 2021
- Fundamental
- Price
- PROK $4.74
- MDXH $2.18
- Analyst Decision
- PROK Buy
- MDXH Buy
- Analyst Count
- PROK 4
- MDXH 1
- Target Price
- PROK $5.33
- MDXH $6.00
- AVG Volume (30 Days)
- PROK 33.1M
- MDXH 61.1K
- Earning Date
- PROK 08-08-2025
- MDXH 08-20-2025
- Dividend Yield
- PROK N/A
- MDXH N/A
- EPS Growth
- PROK N/A
- MDXH N/A
- EPS
- PROK N/A
- MDXH N/A
- Revenue
- PROK $306,000.00
- MDXH $94,507,000.00
- Revenue This Year
- PROK $54.34
- MDXH $23.51
- Revenue Next Year
- PROK N/A
- MDXH $17.68
- P/E Ratio
- PROK N/A
- MDXH N/A
- Revenue Growth
- PROK N/A
- MDXH 25.46
- 52 Week Low
- PROK $0.46
- MDXH $1.35
- 52 Week High
- PROK $7.13
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- PROK 92.14
- MDXH 52.06
- Support Level
- PROK $0.54
- MDXH $2.09
- Resistance Level
- PROK $7.13
- MDXH $2.22
- Average True Range (ATR)
- PROK 0.62
- MDXH 0.10
- MACD
- PROK 0.47
- MDXH -0.01
- Stochastic Oscillator
- PROK 68.59
- MDXH 59.52
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.